Abstract: Disclosed herein are methods of diagnosing pancreatic cancer in a subject. Also provided are methods of monitoring the efficacy of a therapeutic treatment of pancreatic cancer as well as methods of determining the likelihood that a subject having pancreatic cancer will survive, and methods of determining the suitability of a subject having pancreatic cancer for surgical resection therapy.

Abstract: The present invention provides novel genes and proteins for diagnosing ovarian cancer and/or a likelihood for survival, or recurrence of disease, wherein the expresson of the genes and proteins is up-regulated or down-regulated or associated with the occurrence or recurrence of a specific cancer sub-type. The ovarian cancer-associated genes and proteins of the invention are specifically exemplified by the genes and proteins set forth in Tables 1 to 5 and the Sequence Listing.

Abstract: The present invention applies classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen levels from prostate cancer patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to prostate-specific antigen concentration. The present invention provides a method of determining prognosis of prostate cancer and predicting prostate cancer outcome of a patient. The method comprises the steps of first establishing the threshold value of at least one prognostic gene of prostate cancer. Then, the amount of the prognostic gene from a prostate tissue of a prostate cancer patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene, whereby the prognostic outcome of the patient is determined.

Abstract: The present invention provides novel genes and proteins for diagnosing ovarian cancer and/or a likelihood for survival, or recurrence of disease, wherein the expression of the genes and proteins is up-regulated or down-regulated or associated with the occurrence or recurrence of a specific scanner sub-type. The ovarian cancer-associated genes and proteins of the invention are specifically exemplified by the genes and proteins set forth in Tables 1 to 3 and the Sequence Listing.

Abstract: The present invention provides novel genes and proteins for diagnosing pancreatic cancer and/or a likelihood for survival e.g., following surgical resection, wherein the expression of the genes and proteins is up-regulated or down-regulated. The pancreatic cancer-associated genes and proteins of the invention are specifically exemplified by the genes and proteins set forth in Tables 3 to 25 and the Sequence Listing.

Abstract: This invention provides novel methods of detecting or treating aberrant cell cycle regulation associated with expression of a nuclear protein encoded by a gene that is linked to map position 8q22.3 of the human genome, and to novel reagents that are useful therefor. More particularly, the invention provides novel nucleic acid and proteinaceous probes, for detecting a gene that is linked to map position 8q22.3 of the human genome or the expression products thereof, wherein expression or elevated expression of said gene is associated with the appearance or occurrence of tumors associated with cancer, DNA damage and progesterone-receptor-mediated effects on cells. The invention also provides reagents and methods for detecting or modulating the expression products of the gene, such as, for example, in the diagnosis or treatment of cancer, cellular proliferation, DNA damage or progesterone receptor-mediated effects on cells.

Abstract: The present invention provides GPR56 genes and polypeptides encoded therefor. The GPR56 genes of the invention are expressed highly in malignant tissues and the invention also provides diagnostic processes for detecting cancer or malignant tumors in human subjects The diagnostic and prognostic test of the present invention is particularly useful for the early detection of ovarian cancer or metastases thereof and for monitoring the progress of disease, such as, for example, during remission or following surgery or chemotherapy. The GPR56 gene of the invention is also expressed in effector memory T cells, and the invention therefor provides methods of identifying and/or quantifying effector memory T cells, which methods are useful for determining the immune status of a subject.

Abstract: The present invention applies classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen levels from prostate cancer patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to prostate-specific antigen concentration. The present invention provides a method of determining prognosis of prostate cancer and predicting prostate cancer outcome of a patient. The method comprises the steps of first establishing the threshold value of at least one prognostic gene of prostate cancer. Then, the amount of the prognostic gene from a prostate tissue of a prostate cancer patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene, whereby the prognostic outcome of the patient is determined.

Abstract: The present invention provides GPR56 genes and polypeptides encoded therefor. The GPR56 genes of the invention are expressed highly in malignant tissues and the invention also provides diagnostic processes for detecting cancer or malignant tumors in human subjects The diagnostic and prognostic test of the present invention is particularly useful for the early detection of ovarian cancer or metastases thereof and for monitoring the progress of disease, such as, for example, during remission or following surgery or chemotherapy. The GPR56 gene of the invention is also expressed in effector memory T cells, and the invention therefor provides methods of identifying and/or quantifying effector memory T cells, which methods are useful for determining the immune status of a subject.